USPTO serial 97844690
EXPAND
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- ANGOTTI, SALVATORE JOHN
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with EXPAND?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Yuseong-gu, Daejeon, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Janice Housey
JANICE HOUSEY LITMUS LAW PLLCPO BOX 777BERRYVILLE, VA 22611Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations, other than for medical or veterinary purposes; biological preparation for use in experiments other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; biological preparations for use in experiments containing exosomes carrying the desired protein, other than for medical or veterinary use; biochemical preparations for gene recombination for scientific or laboratory purposes; biological tissue cultures, other than for medical or veterinary purposes; cells for scientific or laboratory purposes; biological preparations for scientific or laboratory purposes other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents for use in biological or genetic engineering for scientific or research use and medical laboratory use; reagents for scientific or medical research use; biological preparations for use in biotechnology industry and science, other than for medical purpose; cell growth media for growing cells for use in scientific research; biochemicals for in vitro and in vivo scientific use; reagents for medical research; biological preparation containing exosomes for use in manufacture of cosmetics; protein for use in the manufacture of cosmetics; chemical preparations for use in the manufacture of cosmetics; chemical additives for use in the manufacture of cosmetics; proteins for the food industry | ACTIVE | — |
| 005 | Biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; biochemical preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceuticals featuring drug delivery system, namely, pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; preparations for intracellular drug delivery, namely, drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, patches, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations; pharmaceuticals for the treatment of immune system disease; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cellular diseases; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; protein preparations, namely, protein supplements; biotechnological preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; reagents for medical use; pharmaceuticals for human purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; biochemical pharmaceuticals for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; biological tissue cultures for medical purposes; diagnostic reagents for medical use; pharmaceuticals for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease | ACTIVE | — |
| 042 | Drug discovery services using cells; research on the subject of pharmaceuticals; development of pharmaceutical preparations; biomedical research services; scientific research relating to biology; industrial research in the fields of biology; scientific research consultation and providing scientific information in the fields of biology; scientific research consultation and providing scientific information in the fields of biology; laboratory research in the field of biology; biological research and analysis; biological research services; product development of devices for biological chemicals analysis; product development in the field of biologics; research of biologics, namely, scientific study and research in the field of biologics; research and development of technology for biotechnology; consultancy in the field of biotechnology; biotechnology research; providing scientific research information relating to scientific analysis of the genetic information via online networks; biological information check, namely, genetic testing for scientific research purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 30, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 30, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 10, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 10, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 10, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 21, 2023 | NWAP | NEW APPLICATION ENTERED | — |